AIA
BBC icon

Allegis Investment Advisors’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Allegis Investment Advisors’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-85
Closed -$2K – 251
2015
Q4 		$2K Buy
+85
New +$2.46K ﹤0.01% 971

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

Allegis Investment Advisors's BBC Position: Q1 2016 in Review

Allegis Investment Advisors sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2016, closing a stake of 85 shares — an estimated $2K sold.

Allegis Investment Advisors first reported a position in BBC in Q4 2015 and held it in 1 quarter. The position peaked at $2K in Q4 2015. 12 funds tracked by Wall St. Rank hold BBC as of Q1 2016.

  • Allegis Investment Advisors reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2016 after selling out during the quarter.
  • Allegis Investment Advisors sold 85 Virtus Biotech Clinical Trials ETF shares in Q1 2016, an estimated $2K.
  • Allegis Investment Advisors first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2015 and held it in 1 quarter.
  • Allegis Investment Advisors's Virtus Biotech Clinical Trials ETF position peaked at $2K in Q4 2015.
  • 12 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.